Business
LivaNova to Present Scientific Data on VNS Therapy for Difficult-to-Treat Depression at 4th International Brain Stimulation Conference
LONDON--(BUSINESS WIRE)-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced its participation in the
About this update from Livanova Plc
[{"type":"text","content":" LONDON--(BUSINESS WIRE)--\nLivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced its participation in the 4th International Brain Stimulation Conference, taking place December 6 - 9 in Charleston, S.C. LivaNova will feature clinically meaningful developments around its VNS Therapy® System for the treatment of difficult-to-treat depression.\n\nLivaNova pioneered the VNS Therapy System, which sends mild pulses to the vagus nerve via an implantable device. The company is currently conducting the RECOVER clinical study to examine the efficacy of adjunctive VNS Therapy for people with depression that is difficult to treat.\n\n“Many patients around the world live with major depressive disorder or bipolar disorder and continue to suffer with depressive symptoms despite traditional treatments,” said Bryan Olin, Ph.D. and LivaNova Senior Vice President, Clinical, Quality Assurance and Regulatory Affairs. “For such patients, VNS Therapy can be an effective add-on treatment. We’re eager to present the latest updates on this safe and effective treatment and demonstrate how it is making a difference for patients struggling with these chronic and debilitating diseases.”\n\nAt the Brain Stimulation Conference, LivaNova employees and key opinion leader clinicians will present five scientific posters related to depression clinical studies and treatments, including VNS Therapy:\n\n\n“Vagus Nerve Stimulation in Patients Receiving Maintenance Therapy with Electroconvulsive Therapy: A Series of 10 Cases.” Presented by Dr. Scott T. Aaronson, Director, Clinical Research Programs, Sheppard Pratt Health System, Baltimore, Maryland, on Tuesday, December 7 from 12:30 to 1:45 p.m. Eastern.\n\n\n“A prospective, multi-center randomized, controlled, blinded trial of vagus nerve stimulation for difficult-to-treat depression: A novel design for a novel treatment.” Presented by Bryan Olin, Ph.D., Senior Vice President of Clinical, Quality Assurance and Regulatory Affairs at LivaNova, on Wednesday, December 8 from 12 to 1:30 p.m. Eastern.\n\n\n“Chronic Vagus Nerve Stimulation Significantly Improves Quality of Life in Treatment-Resistant Major Depression.” Presented by Dr. Charles Conway, Director of the Washington University Resistant Mood Disorders Center, Washington University in St. Louis School of Medicine, S...